EMA Authorised: Uptravi (selexipag) — Janssen Cilag International NV

View source ↗

Summary

The European Medicines Agency authorised Uptravi (selexipag) from Janssen Cilag International NV for pulmonary arterial hypertension.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• Uptravi (selexipag)

Snippet

Status: Authorised. Therapeutic area: Hypertension, Pulmonary. MAH: Janssen Cilag International NV. Decision date: 18/02/2026